Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion CancersJanuary 7, 2021Sharefile does not exist at PATH: /nas/content/live/sofinnova/build/images/icons/facebook.svgfile does not exist at PATH: /nas/content/live/sofinnova/build/images/icons/linkedin.svgfile does not exist at PATH: /nas/content/live/sofinnova/build/images/icons/twitter.svgSharefile does not exist at PATH: /nas/content/live/sofinnova/build/images/icons/facebook.svgfile does not exist at PATH: /nas/content/live/sofinnova/build/images/icons/linkedin.svgfile does not exist at PATH: /nas/content/live/sofinnova/build/images/icons/twitter.svg
